OBI Pharma bags FDA Orphan Drug Designation for cancer drug, OBI-999
Category: #health  By Saipriya Iyer  Date: 2019-12-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

OBI Pharma bags FDA Orphan Drug Designation for cancer drug, OBI-999

Taiwan-based biopharmaceutical firm, OBI Pharma, Inc. has reportedly been granted the Orphan Drug Designation by the U.S. FDA (Food and Drug Administration) for Pancreatic Cancer treatment OBI-999. Sources claim that the Phase 1/2 clinical trial of OBI-999 was commenced at the University of Texas M.D. Anderson Cancer Center in patients with locally advanced or metastatic solid tumors, including pancreatic, colorectal, gastric, and esophageal cancers.

The trial aimed at verifying the preliminary efficacy and safety of OBI-999 in patient who are already diagnosed with per protocol tumor types, including pancreatic and colorectal, cancers of high unmet clinical needs.

According to a statement, Tillman Pearce, CMO, OBI Pharma, said that their firm is thrilled about the potential value of OBI-999 that it would provide to patients with pancreatic cancer, given to the high potency observed using OBI-999 in pancreatic cancer xenograft models.

Pancreatic cancer usually originates in the endocrine or exocrine pancreatic cells and is likely to be caused by smoking, poor diet, and genetic factors. It is a deadly disease that reportedly affects around 69,839 people in the U.S. with a survival rate of only 8.5% at five years. Its treatment options are limited to surgical resection for patients with early stages of pancreatic cancer and may only have a five-year survival rate of up to 34.3%.

Meanwhile, as a potential treatment, OBI-999 is a first-in-class ADC (Antibody Drug Conjugate) with exclusive linker technology that offers consistent DAR (Drug-to-Antibody ratio) for cancer treatment that is based on Globo H.

The drug makes use of Globo H antibody to focus on cancer cells the possess higher Globo H expression. By letting out a small molecule chemotherapeutic drug through the specificity of the antibody, OBI-999 directly deploys cytotoxic therapy at the targeted cancer cells.

Source Credit: https://finance.yahoo.com/news/obi-pharma-granted-fda-orphan-100000544.html?guccounter=1



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...